Merck Mavenclad (Krakowbin tablets) approved by the Swiss Medical Products Authority for the treatment of recurrent remission multiple sclerosis

recently, Merck KGaA announced that Mavenclad (cladrine tablets) has been approved by the SwissMedical(http://product(http://Authority for the treatment of highly active recurrent recurrent multiple sclerosis (RRMS)Mavenclad is the first RRMSdrug(http://that can be controlled for up to 4 years or ally for up to 20 days over a two-year periodAbout Mavenclad
Mavenclad's active drug ingredient, cladribine, is a carnitine analogue, asynthetic(http://chemotherapy drug targeting lymphocytes, with the option of sexually suppressing the immune systemIt mimics adenosine chemically, which inhibits adenosine deaminase and interferes with the ability of cells to synthesize DNAcladribine is activated only by lymphocytes, the inactive cladribine will be removed from all other cells quicklyMavenclad is a short-term oral therapy in which selective and periodic targeting is considered essential for recurrent multiple sclerosis (RMS) pathologyIn August 2017, Mavenclad was approved for RMS in 28 countries in the European Union, and the drug is now approved in more than 50 countriesIn the United States, Mavenclad has not yet approved any usesThe studyMavenclad has demonstrated lasting clinical efficacy for up to 4 years in key indicators of disease activity, including disability progression, annual recurrence rate, and magnetic resonance imaging (MRI) activityMavenclad's approval is based on data from more than 10,000 patient years, and the clinicaltrial(http://program includes more than 2,700 patients, some of whose observation period is up to 10 yearsClinical development projects include data from three placebo-controlled Phase III clinical trials (CLARITY (CLARITY (Key Efficacy Study), CLARITY EXTENSION, ORACLE MS, Phase II ONWARD Study, and long-term follow-up data from 8-year prospective registered studiesThe efficacy and safety results of these studies establish the complete benefit risk characteristics of MavencladPost-mortemanalysis(http://data from the 2-year PHASE III CLARITY study showed that in patients with high disease activity, Mavenclad reduced the annual recurrence rate by 67 percent compared to placebo and reduced the risk of progression of the six-month extended disability scale (EDSS) by 82 percent As shown in the Phase III CLARITY EXTENSION study, no further Mavenclad treatment is required in years 3 and 4 Mavenclad has good safety characteristics, has been observed in some patients for up to 10 years, and has not been reported for multiple sclerosis (MS) The most clinically relevant adverse reactions are lymphocyte reduction and shingles Lymphocytes must be evaluated before and during treatment with Mavenclad Mavenclad is prohibited for use in certain populations, including patients with immunocompromised function and pregnant women